Project Grant R01AI198251
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $710K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Notre Dame, IN 46556, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded the University of Notre Dame DU Lac $158,000 on June 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct spatial mapping research on Pseudomonas aeruginosa biofilm organization and stress resilience. The research combines multiple spatial analytical techniques—fluorescence microscopy, polarized light microscopy, and confocal Raman microscopy—to map the localization of alkyl quinolones...
- The National Institute of Allergy and Infectious Diseases awarded the University of Notre Dame $769,354 on May 22, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to elucidate spore germination machinery in Clostridioides difficile and optimize a class of antibiotics called oxadiazoles as spore germination inhibitors. The research addresses recurrent C. difficile infections, which occur in approximately 25 percent of patients and represent a significant source of...
- The National Institute of Allergy and Infectious Diseases awarded the University of Notre Dame DU Lac $748,964 on May 22, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop boron-based small-molecule inhibitors that restore antibiotic sensitivity in methicillin-resistant Staphylococcus aureus (MRSA). The research targets the BlaR protein, a β-lactam sensor on the bacterial cell membrane that triggers antibiotic resistance when activated. Designer boronate...
- The National Institute of Allergy and Infectious Diseases awarded the University of Notre Dame Du Lac $197,500 on June 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how tyloxapol inhibits mycobacterial type VII secretory activity. The research addresses the molecular mechanisms by which tyloxapol, a non-ionic detergent, impairs the ESX-1 secretion system essential for mycobacterial infection. Preliminary data demonstrate that sub-critical...
- The National Institute of Allergy and Infectious Diseases awarded the University of Notre Dame DU Lac $434,500 under Project Grant R21AI190342 on August 5, 2026, to conduct research targeting biofilm formation as a mechanism to enhance antibiotic efficacy against Mycobacterium avium and M. abscessus. The research aims to identify 2-aminoimidazole and related compounds that block and disrupt mycobacterial biofilm formation. Aim 1 involves screening existing and new 2-aminoimidazole compounds...
- The National Institute of Allergy and Infectious Diseases awarded the University of Notre Dame $614,655 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate bladder inflammatory and immune responses to fungal catheter-associated urinary tract infections caused by Candida albicans. The research addresses a significant knowledge gap in understanding fungal catheter-associated urinary tract infections, which now represent the second leading...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded $571,412 to the University of Maryland, College Park on June 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research into the regulation of bacterial physiology and infections through linear diribonucleotides and RNA degradation. The project will characterize how diribonucleases and triribonucleases bind their respective...
- The National Institute of Allergy and Infectious Diseases awarded Northwestern University $431,784 on February 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on Pseudomonas aeruginosa carriage in the gastrointestinal tract. The funded research investigates how hospitalized patients acquire P. aeruginosa colonization in the GI tract, which serves as a major reservoir for subsequent spread to other body sites and infection. The recipient will...
- The National Institute of Allergy and Infectious Diseases awarded New York University $742,364 on August 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate autolysin control pathways in Pseudomonas aeruginosa. The research examines how bacteria regulate cell wall-degrading enzymes (autolysins) to control their activity during cell growth and division. Pseudomonas aeruginosa serves as the model organism because it causes serious human infections...
- The National Institute of Allergy and Infectious Diseases (NIAID), a component of the Department of Health and Human Services National Institutes of Health, awarded the University of Notre Dame $237,000 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop monoclonal antibody-conjugated nanoparticles for targeted cytomegalovirus antiviral delivery. The project addresses limitations of current CMV therapies—ganciclovir and valganciclovir—which...